Key result
A new risk prediction model for life-threatening ventricular tachyarrhythmias in laminopathies yielded a validation C-index of 0.800 (95% CI 0.642-0.959) and net reclassified 28.8% of patients.
Why the study?
Accurate estimation of the risk of life-threatening ventricular tachyarrhythmia in patients with LMNA mutations is crucial to select candidates for implantable cardioverter-defibrillator implantation.
Does a new risk prediction model improve the prediction of life-threatening ventricular tachyarrhythmias and selection for ICD implantation in adult patients with LMNA mutations compared to current guidelines?
Population
839 adult patients with LMNA mutations
Comparison
Risk prediction score vs current clinical practice guidelines
Design
Derivation and external validation cohort study
Follow-up
Median 3.6 years (derivation) and 5.1 years (validation)
Authors
Loading...
Supports refined ICD selection in LMNA carriers via validated 7% threshold; extends guidelines but needs prospective confirmation.
Cohort (n=839)
Yes
Does a new risk prediction model improve the prediction of life-threatening ventricular tachyarrhythmias and selection for ICD implantation in adult patients with LMNA mutations compared to current guidelines?
Effect estimate: C-index 0.800 (95% CI 0.642-0.959)
A novel risk prediction model for life-threatening ventricular tachyarrhythmias in patients with LMNA mutations significantly improves risk stratification and reclassifies nearly 30% of patients compared to current guidelines.
Wahbi et al. (2019) conducted a cohort in Laminopathies (LMNA mutations) (n=839). Risk prediction model for life-threatening ventricular tachyarrhythmias vs. Current clinical practice guidelines was evaluated on Life-threatening ventricular tachyarrhythmia (sudden cardiac death or ICD-treated/hemodynamically unstable VTA) (C-index 0.800, 95% CI 0.642-0.959). A new risk prediction model for life-threatening ventricular tachyarrhythmias in laminopathies yielded a validation C-index of 0.800 (95% CI 0.642-0.959) and net reclassified 28.8% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: